EA011400B1 - Лекарственные формы модафинила с модифицированным высвобождением - Google Patents

Лекарственные формы модафинила с модифицированным высвобождением Download PDF

Info

Publication number
EA011400B1
EA011400B1 EA200600590A EA200600590A EA011400B1 EA 011400 B1 EA011400 B1 EA 011400B1 EA 200600590 A EA200600590 A EA 200600590A EA 200600590 A EA200600590 A EA 200600590A EA 011400 B1 EA011400 B1 EA 011400B1
Authority
EA
Eurasian Patent Office
Prior art keywords
modafinil
dosage form
release
form according
modafinil compound
Prior art date
Application number
EA200600590A
Other languages
English (en)
Russian (ru)
Other versions
EA200600590A1 (ru
Inventor
Алпа Парикх
Пиюш Р. Пейтел
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34381093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA011400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA200600590A1 publication Critical patent/EA200600590A1/ru
Publication of EA011400B1 publication Critical patent/EA011400B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA200600590A 2003-09-18 2004-09-20 Лекарственные формы модафинила с модифицированным высвобождением EA011400B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50402803P 2003-09-18 2003-09-18
US10/944,528 US8153159B2 (en) 2003-09-18 2004-09-17 Modafinil modified release pharmaceutical compositions
PCT/US2004/030815 WO2005027890A1 (en) 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
EA200600590A1 EA200600590A1 (ru) 2006-08-25
EA011400B1 true EA011400B1 (ru) 2009-02-27

Family

ID=34381093

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600590A EA011400B1 (ru) 2003-09-18 2004-09-20 Лекарственные формы модафинила с модифицированным высвобождением

Country Status (20)

Country Link
US (1) US8153159B2 (https=)
EP (1) EP1670447B1 (https=)
JP (1) JP5138932B2 (https=)
KR (1) KR20060117910A (https=)
AR (1) AR046410A1 (https=)
AT (1) ATE448780T1 (https=)
AU (1) AU2004274017B2 (https=)
BR (1) BRPI0414299A (https=)
CA (1) CA2536666C (https=)
DE (1) DE602004024220D1 (https=)
EA (1) EA011400B1 (https=)
ES (1) ES2336215T3 (https=)
IL (1) IL173738A (https=)
IS (1) IS2787B (https=)
MX (1) MXPA06003125A (https=)
MY (1) MY144755A (https=)
NO (1) NO20060964L (https=)
NZ (1) NZ545573A (https=)
TW (1) TWI344840B (https=)
WO (1) WO2005027890A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
EP1755388B1 (en) * 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
AU2007214487A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20090082461A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched modafinil
JP5250285B2 (ja) * 2008-03-26 2013-07-31 富士フイルム株式会社 経口物用被覆材、可食性容器およびそれらを用いた経口物
WO2010012407A1 (en) * 2008-07-29 2010-02-04 Ashland Licensing And Intellectual Property Llc. Modified additives for suppressing dust formation
KR101465077B1 (ko) * 2010-07-06 2014-11-26 주식회사 네비팜 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
EP3137060B2 (en) 2014-05-01 2023-12-20 Sun Pharmaceutical Industries Ltd Extended release suspension compositions
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
BR112020000318A2 (pt) * 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038863A1 (en) * 2000-02-23 2001-11-08 Christof Jaenicke Pharmaceutical with predetermined activity profile
WO2002096401A1 (en) * 2001-05-25 2002-12-05 Cephalon, Inc. Solid pharmaceutical formulations comprising modafinil
WO2004024134A1 (en) * 2002-09-13 2004-03-25 Cephalon, Inc. Pharmaceutical formulations of modafinil

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010038863A1 (en) * 2000-02-23 2001-11-08 Christof Jaenicke Pharmaceutical with predetermined activity profile
WO2002096401A1 (en) * 2001-05-25 2002-12-05 Cephalon, Inc. Solid pharmaceutical formulations comprising modafinil
WO2004024134A1 (en) * 2002-09-13 2004-03-25 Cephalon, Inc. Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
EP1670447A1 (en) 2006-06-21
IL173738A0 (en) 2006-07-05
ES2336215T3 (es) 2010-04-09
IL173738A (en) 2012-07-31
TW200520748A (en) 2005-07-01
WO2005027890A1 (en) 2005-03-31
DE602004024220D1 (de) 2009-12-31
AR046410A1 (es) 2005-12-07
IS2787B (is) 2012-06-15
EA200600590A1 (ru) 2006-08-25
US8153159B2 (en) 2012-04-10
AU2004274017A1 (en) 2005-03-31
ATE448780T1 (de) 2009-12-15
NO20060964L (no) 2006-04-18
NZ545573A (en) 2010-02-26
US20050095294A1 (en) 2005-05-05
MY144755A (en) 2011-10-31
KR20060117910A (ko) 2006-11-17
TWI344840B (en) 2011-07-11
HK1089697A1 (en) 2006-12-08
JP2007518696A (ja) 2007-07-12
EP1670447B1 (en) 2009-11-18
CA2536666A1 (en) 2005-03-31
AU2004274017B2 (en) 2010-07-08
MXPA06003125A (es) 2006-06-20
CA2536666C (en) 2012-06-19
JP5138932B2 (ja) 2013-02-06
BRPI0414299A (pt) 2006-11-14
IS8327A (is) 2006-02-23

Similar Documents

Publication Publication Date Title
CN101522176B (zh) 氟班色林的制剂及其制备方法
KR101612931B1 (ko) 1일 1회 투여로 약리학적 임상 효과를 제공하는 모사프리드 서방성 제제
US9532954B2 (en) Controlled release and taste masking oral pharmaceutical compositions
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
JP2013501810A (ja) 医薬組成物
CN101784266B (zh) 氢溴酸安非他酮以及治疗的应用
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
JP5276989B2 (ja) ネラメキサン放出調節マトリックス錠
KR20110117216A (ko) Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
CN102036656A (zh) 含有蜡的缓释制剂
JP2009502987A (ja) カルビドパとレボドパを含有する延長放出型固形医薬組成物
EA011400B1 (ru) Лекарственные формы модафинила с модифицированным высвобождением
WO2007054976A2 (en) Lipid based controlled release pharmaceutical composition
EP2533767A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
NO20121414A1 (no) Farmasoytiske sammensetninger omfattende hydromorfon og nalokson
KR20140045925A (ko) 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
KR20080013927A (ko) 벤라팍스의 하나 이상 형태의 개질 방출 조성물
WO2015063670A1 (en) Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
CN101031290B (zh) 改良释放的莫达非尼药物组合物
KR20170001545A (ko) 모사프리드 서방성 제제 및 모사프리드와 라베프라졸의 복합제제
WO2010023693A2 (en) Novel controlled release compositions of ropinirole
HK1089697B (en) Modafinil modified release pharmaceutical compositions
HK1142811B (en) Bupropion hydrobromide and therapeutic applications

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU